Some three million people in France suffer from what is described as the"unmentionable" illness of incontinence - still a taboo subject socially.
However, a new law is to be introduced shortly which will enable treatment for the condition to be reimbursed under a payments regime that will apply specifically to dependency among the elderly, and which will be fixed at a percentage of total dependency payments.
Such reimbursements will cover hygiene products and medical treatments in a market estimated to be worth some 1.2 billion French francs ($205.4 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze